Inactive Instrument

Concert Pharmaceuticals, Inc.

CNCE

US2060221056

Biotechnology & Medical Research

Concert: Q3 Earnings Snapshot

November 07, 2022 at 07:07 am EST

LEXINGTON, Mass. (AP) _ Concert Pharmaceuticals Inc. (CNCE) on Monday reported a loss of $28.9 million in its third quarter.

The Lexington, Massachusetts-based company said it had a loss of 58 cents per share.

The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 59 cents per share.

The biopharmaceutical company posted revenue of $8,000 in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CNCE at https://www.zacks.com/ap/CNCE

Latest news about Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces the Presentation of Data from its Phase 3 Clinical Trial, THRIVE-AA2	23-03-18	CI
Sun Pharmaceutical Completes Acquisition of Concert Pharmaceuticals	23-03-06	MT
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from NASDAQ Composite Index	23-03-06	CI
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from S&P Global BMI Index	23-03-06	CI
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from S&P TMI Index	23-03-06	CI
Sun Pharmaceutical Industries Limited completed the acquisition of Concert Pharmaceuticals, Inc..	23-03-05	CI
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from NASDAQ Biotechnology Index	23-03-03	CI
North American Morning Briefing : Rising Yields -3-	23-03-02	DJ
Concert Pharmaceuticals Says Deuruxolitinib Maintains FDA Breakthrough Therapy Designation to Treat Alopecia Areata	23-02-15	MT
Concert Pharmaceuticals, Inc. Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata	23-02-15	CI
Insider Sell: Concert Pharmaceuticals	23-01-31	MT
North American Morning Briefing : Stock Futures -3-	23-01-23	DJ
JMP Securities Downgrades Concert Pharmaceuticals to Market Perform From Market Outperform	23-01-20	MT
Truist Downgrades Concert Pharmaceuticals to Hold Rating From Buy, Adjusts Price Target to $9 From $25	23-01-20	MT
Jefferies Downgrades Concert Pharmaceuticals to Hold From Buy, Adjusts Price Target to $9 From $15	23-01-20	MT
JonesTrading Downgrades Concert Pharmaceuticals to Hold From Buy	23-01-20	MT
Indian shares set for muted start on rate hike concerns	23-01-19	RE
Sun Pharmaceutical to Acquire US-Based Concert Pharmaceuticals in $576 Million Deal	23-01-19	MT
Health Care Up Amid Deal Activity -- Health Care Roundup	23-01-19	DJ
Sector Update: Healthcare Stocks Gain on Thursday	23-01-19	MT
Sector Update: Health Care Stocks Grinding Out Modest Gains	23-01-19	MT
Sector Update: Health Care	23-01-19	MT
Concert Pharmaceuticals Shares Rally on Takeover by Sun	23-01-19	DJ
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday	23-01-19	MT
Sector Update: Health Care	23-01-19	MT

Chart Concert Pharmaceuticals, Inc.

Duration

Period

More charts

Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The Company is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The Company is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+56.00%	55.07B
IQVIA HOLDINGS INC.	-1.88%	41.79B
LONZA GROUP AG	+44.53%	40.22B
CELLTRION, INC.	-7.59%	28.17B
ICON PUBLIC LIMITED COMPANY	+12.16%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.02%	18.93B
BIO-TECHNE CORPORATION	+6.98%	13.03B
MEDPACE HOLDINGS, INC.	+29.33%	12.26B
UNITED THERAPEUTICS CORPORATION	+26.20%	12.21B

Other Biotechnology & Medical Research

Concert Pharmaceuticals, Inc.

Equities

CNCE

US2060221056

Biotechnology & Medical Research

Concert: Q3 Earnings Snapshot

Latest news about Concert Pharmaceuticals, Inc.

Chart Concert Pharmaceuticals, Inc.

Company Profile

Sector Other Biotechnology & Medical Research